<DOC>
	<DOC>NCT00824291</DOC>
	<brief_summary>This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained release (DVS SR) or placebo for 12 weeks.</brief_summary>
	<brief_title>Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Outpatient men and women, between the ages of 18 to 75 years, fluent in both written and spoken English. Employed for 20 hours or more for a minimum of 1 month prior to baseline. Primary diagnosis of Major Depressive Disorder with symptoms for at least 30 days prior to baseline. Treatment with desvenlafaxine succinate sustained release at any time in the past and/or venlafaxine (Effexor or Effexor XR) 1 year prior to baseline. Treatmentresistant defined as any of the following failed treatments in the past 3 years: 3 or more previous adequate trials of &gt;=2 classes of antidepressant medication, electroconvulsive therapy, or psychotherapy (2 adequate trials). Current (within 12 months prior to the screening visit) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessivecompulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder. Clinically important abnormalities on physical examination, electrocardiogram (ECG), or laboratory evaluations.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Major Depressive Disorder</keyword>
</DOC>